{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T09:05:08Z","timestamp":1774083908816,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T00:00:00Z","timestamp":1686182400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T00:00:00Z","timestamp":1686182400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"China and partly supported by China National Major Project for New Drug Innovation","award":["2017ZX09304015"],"award-info":[{"award-number":["2017ZX09304015"]}]},{"name":"Genor Biopharma Co., Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s00262-023-03467-7","type":"journal-article","created":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T09:02:26Z","timestamp":1686214946000},"page":"2991-3002","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of geptanolimab (GB226) for relapsed\/refractory primary mediastinal large B-cell lymphoma: an open-label phase II study (Gxplore-003)"],"prefix":"10.1007","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3342-4964","authenticated-orcid":false,"given":"Yuankai","family":"Shi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liqun","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junning","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhuan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoling","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhigang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liping","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huilai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weihua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liye","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Genny","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenduo","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,8]]},"reference":[{"key":"3467_CR1","doi-asserted-by":"publisher","unstructured":"Alaggio R, Amador C, Anagnostopoulos I et al. (2022) The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia, 36:1720\u20131748. Doi: https:\/\/doi.org\/10.1038\/s41375-022-01620-2","DOI":"10.1038\/s41375-022-01620-2"},{"key":"3467_CR2","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1084\/jem.20031074","volume":"198","author":"A Rosenwald","year":"2003","unstructured":"Rosenwald A, Wright G, Leroy K et al (2003) Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 198:851\u2013862. https:\/\/doi.org\/10.1084\/jem.20031074","journal-title":"J Exp Med"},{"key":"3467_CR3","doi-asserted-by":"publisher","first-page":"3871","DOI":"10.1182\/blood-2003-06-1841","volume":"102","author":"KJ Savage","year":"2003","unstructured":"Savage KJ, Monti S, Kutok JL et al (2003) The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 102:3871\u20133879. https:\/\/doi.org\/10.1182\/blood-2003-06-1841","journal-title":"Blood"},{"key":"3467_CR4","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1111\/bjh.14951","volume":"179","author":"L Giulino-Roth","year":"2017","unstructured":"Giulino-Roth L, O\u2019Donohue T, Chen Z et al (2017) Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R. Br J Haematol 179:739\u2013747. https:\/\/doi.org\/10.1111\/bjh.14951","journal-title":"Br J Haematol"},{"key":"3467_CR5","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1182\/blood.2019004296","volume":"136","author":"AR Hayden","year":"2020","unstructured":"Hayden AR, Tonseth P, Lee DG et al (2020) Outcome of primary mediastinal large B-cell lymphoma using R-CHOP: impact of a PET-adapted approach. Blood 136:2803\u20132811. https:\/\/doi.org\/10.1182\/blood.2019004296","journal-title":"Blood"},{"key":"3467_CR6","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1200\/JCO.2013.51.7524","volume":"32","author":"M Martelli","year":"2014","unstructured":"Martelli M, Ceriani L, Zucca E et al (2014) [18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study. J Clin Oncol 32:1769\u20131775. https:\/\/doi.org\/10.1200\/JCO.2013.51.7524","journal-title":"J Clin Oncol"},{"key":"3467_CR7","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.3324\/haematol.2018.192492","volume":"103","author":"C Melani","year":"2018","unstructured":"Melani C, Advani R, Roschewski M et al (2018) End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision making. Haematologica 103:1337\u20131344. https:\/\/doi.org\/10.3324\/haematol.2018.192492","journal-title":"Haematologica"},{"key":"3467_CR8","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1093\/annonc\/mdq418","volume":"22","author":"M Rieger","year":"2011","unstructured":"Rieger M, Osterborg A, Pettengell R et al (2011) Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study. Ann Oncol 22:664\u2013670. https:\/\/doi.org\/10.1093\/annonc\/mdq418","journal-title":"Ann Oncol"},{"key":"3467_CR9","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1093\/annonc\/mdj030","volume":"17","author":"KJ Savage","year":"2006","unstructured":"Savage KJ, Al-Rajhi N, Voss N, Paltiel C, Klasa R, Gascoyne RD, Connors JM (2006) Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. Ann Oncol 17:123\u2013130. https:\/\/doi.org\/10.1093\/annonc\/mdj030","journal-title":"Ann Oncol"},{"key":"3467_CR10","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1080\/10428190802108870","volume":"49","author":"J Kuruvilla","year":"2008","unstructured":"Kuruvilla J, Pintilie M, Tsang R, Nagy T, Keating A, Crump M (2008) Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma. Leuk Lymphoma 49:1329\u20131336. https:\/\/doi.org\/10.1080\/10428190802108870","journal-title":"Leuk Lymphoma"},{"key":"3467_CR11","doi-asserted-by":"publisher","first-page":"e372","DOI":"10.1038\/bcj.2015.101","volume":"5","author":"T Aoki","year":"2015","unstructured":"Aoki T, Shimada K, Suzuki R et al (2015) High-dose chemotherapy followed by autologous stem cell transplantation for relapsed\/refractory primary mediastinal large B-cell lymphoma. Blood Cancer J 5:e372. https:\/\/doi.org\/10.1038\/bcj.2015.101","journal-title":"Blood Cancer J"},{"key":"3467_CR12","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41408-020-0312-7","volume":"10","author":"H Zhou","year":"2020","unstructured":"Zhou H, Xu-Monette ZY, Xiao L et al (2020) Prognostic factors, therapeutic approaches, and distinct immunobiologic features in patients with primary mediastinal large B-cell lymphoma on long-term follow-up. Blood Cancer J 10:49. https:\/\/doi.org\/10.1038\/s41408-020-0312-7","journal-title":"Blood Cancer J"},{"key":"3467_CR13","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1182\/blood-2011-05-326538","volume":"118","author":"C Steidl","year":"2011","unstructured":"Steidl C, Gascoyne RD (2011) The molecular pathogenesis of primary mediastinal large B-cell lymphoma. Blood 118:2659\u20132669. https:\/\/doi.org\/10.1182\/blood-2011-05-326538","journal-title":"Blood"},{"key":"3467_CR14","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1182\/blood-2017-01-764258","volume":"129","author":"PL Zinzani","year":"2017","unstructured":"Zinzani PL, Pellegrini C, Chiappella A, Di Rocco A, Salvi F, Cabras MG, Argnani L, Stefoni V (2017) Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial. Blood 129:2328\u20132330. https:\/\/doi.org\/10.1182\/blood-2017-01-764258","journal-title":"Blood"},{"key":"3467_CR15","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL et al (2017) Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 377:2531\u20132544. https:\/\/doi.org\/10.1056\/NEJMoa1707447","journal-title":"N Engl J Med"},{"key":"3467_CR16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL, Ghobadi A, Jacobson CA et al (2019) Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol 20:31\u201342. https:\/\/doi.org\/10.1016\/S1470-2045(18)30864-7","journal-title":"Lancet Oncol"},{"key":"3467_CR17","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson JS, Palomba ML, Gordon LI et al (2020) Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396:839\u2013852. https:\/\/doi.org\/10.1016\/S0140-6736(20)31366-0","journal-title":"Lancet"},{"key":"3467_CR18","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1182\/blood.2020008376","volume":"140","author":"KJ Savage","year":"2022","unstructured":"Savage KJ (2022) Primary mediastinal large B-cell lymphoma. Blood 140:955\u2013970. https:\/\/doi.org\/10.1182\/blood.2020008376","journal-title":"Blood"},{"key":"3467_CR19","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","volume":"116","author":"MR Green","year":"2010","unstructured":"Green MR, Monti S, Rodig SJ et al (2010) Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 116:3268\u20133277. https:\/\/doi.org\/10.1182\/blood-2010-05-282780","journal-title":"Blood"},{"key":"3467_CR20","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1182\/blood-2013-10-535443","volume":"123","author":"DD Twa","year":"2014","unstructured":"Twa DD, Chan FC, Ben-Neriah S et al (2014) Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. Blood 123:2062\u20132065. https:\/\/doi.org\/10.1182\/blood-2013-10-535443","journal-title":"Blood"},{"key":"3467_CR21","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1200\/JCO.19.01389","volume":"37","author":"P Armand","year":"2019","unstructured":"Armand P, Rodig S, Melnichenko V et al (2019) Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma. J Clin Oncol 37:3291\u20133299. https:\/\/doi.org\/10.1200\/JCO.19.01389","journal-title":"J Clin Oncol"},{"key":"3467_CR22","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1182\/blood-2016-12-758383","volume":"130","author":"PL Zinzani","year":"2017","unstructured":"Zinzani PL, Ribrag V, Moskowitz CH et al (2017) Safety and tolerability of pembrolizumab in patients with relapsed\/refractory primary mediastinal large B-cell lymphoma. Blood 130:267\u2013270. https:\/\/doi.org\/10.1182\/blood-2016-12-758383","journal-title":"Blood"},{"key":"3467_CR23","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32:3059\u20133068. https:\/\/doi.org\/10.1200\/JCO.2013.54.8800","journal-title":"J Clin Oncol"},{"key":"3467_CR24","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1200\/jop.18.00005","volume":"14","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Thompson JA (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary. J oncol Pract 14:247\u2013249. https:\/\/doi.org\/10.1200\/jop.18.00005","journal-title":"J oncol Pract"},{"key":"3467_CR25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.cpt.2022.09.006","volume":"1","author":"Y Shi","year":"2023","unstructured":"Shi Y, Chen H, Qin Y et al (2023) Clinical characteristics and treatment outcomes of Chinese diffuse large B-cell lymphoma patients in the era of rituximab (2005\u20132018)\u2606. Cancer Pathog Ther 1:3\u201311","journal-title":"Cancer Pathog Ther"},{"key":"3467_CR26","doi-asserted-by":"publisher","first-page":"100097","DOI":"10.1016\/j.lanwpc.2021.100097","volume":"8","author":"H Chen","year":"2021","unstructured":"Chen H, Zhou Y, Han X, Shi Y (2021) The changing landscape of anti-lymphoma drug clinical trials in mainland China in the past 15 years (2005\u20132020): a systematic review. Lancet Reg Health West Pac 8:100097. https:\/\/doi.org\/10.1016\/j.lanwpc.2021.100097","journal-title":"Lancet Reg Health West Pac"},{"key":"3467_CR27","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s12185-018-2404-8","volume":"107","author":"Y Shi","year":"2018","unstructured":"Shi Y (2018) Current status and progress of lymphoma management in China. Int J Hematol 107:405\u2013412. https:\/\/doi.org\/10.1007\/s12185-018-2404-8","journal-title":"Int J Hematol"},{"key":"3467_CR28","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1182\/blood.2019000847","volume":"135","author":"J Kline","year":"2020","unstructured":"Kline J, Godfrey J, Ansell SM (2020) The immune landscape and response to immune checkpoint blockade therapy in lymphoma. Blood 135:523\u2013533. https:\/\/doi.org\/10.1182\/blood.2019000847","journal-title":"Blood"},{"key":"3467_CR29","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1016\/j.celrep.2015.10.008","volume":"13","author":"A Mottok","year":"2015","unstructured":"Mottok A, Woolcock B, Chan FC et al (2015) Genomic alterations in CIITA are frequent in primary mediastinal large B cell lymphoma and are associated with diminished MHC class II expression. Cell Rep 13:1418\u20131431. https:\/\/doi.org\/10.1016\/j.celrep.2015.10.008","journal-title":"Cell Rep"},{"key":"3467_CR30","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/nature09754","volume":"471","author":"C Steidl","year":"2011","unstructured":"Steidl C, Shah SP, Woolcock BW et al (2011) MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature 471:377\u2013381. https:\/\/doi.org\/10.1038\/nature09754","journal-title":"Nature"},{"key":"3467_CR31","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1182\/blood.2019002067","volume":"134","author":"B Chapuy","year":"2019","unstructured":"Chapuy B, Stewart C, Dunford AJ et al (2019) Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade. Blood 134:2369\u20132382. https:\/\/doi.org\/10.1182\/blood.2019002067","journal-title":"Blood"},{"key":"3467_CR32","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le DT, Uram JN, Wang H et al (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372:2509\u20132520. https:\/\/doi.org\/10.1056\/NEJMoa1500596","journal-title":"N Engl J Med"},{"key":"3467_CR33","doi-asserted-by":"publisher","first-page":"3924","DOI":"10.1038\/s41388-018-0245-9","volume":"37","author":"S Wang","year":"2018","unstructured":"Wang S, Jia M, He Z, Liu XS (2018) APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer. Oncogene 37:3924\u20133936. https:\/\/doi.org\/10.1038\/s41388-018-0245-9","journal-title":"Oncogene"},{"key":"3467_CR34","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1016\/S2352-3026(18)30192-3","volume":"6","author":"Y Shi","year":"2019","unstructured":"Shi Y, Su H, Song Y et al (2019) Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial. Lancet Haematol 6:e12\u2013e19. https:\/\/doi.org\/10.1016\/S2352-3026(18)30192-3","journal-title":"Lancet Haematol"},{"key":"3467_CR35","doi-asserted-by":"publisher","first-page":"8034","DOI":"10.1200\/JCO.2020.38.15_suppl.8034","volume":"38","author":"H Su","year":"2020","unstructured":"Su H, Song Y, Jiang W et al (2020) Sintilimab for relapsed\/refractory classical Hodgkin\u2019s lymphoma: long-term follow-up on the multicenter, single-arm phase II ORIENT-1 study. J Clin Oncol 38:8034. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.8034","journal-title":"J Clin Oncol"},{"key":"3467_CR36","doi-asserted-by":"publisher","first-page":"6445","DOI":"10.1158\/1078-0432.CCR-20-2819","volume":"26","author":"Y Shi","year":"2020","unstructured":"Shi Y, Cai Q, Jiang Y et al (2020) Activity and safety of geptanolimab (GB226) for patients with unresectable, recurrent, or metastatic alveolar soft part sarcoma: a phase II. Single-arm Study Clin Cancer Res 26:6445\u20136452. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-2819","journal-title":"Single-arm Study Clin Cancer Res"},{"key":"3467_CR37","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13045-021-01033-1","volume":"14","author":"Y Shi","year":"2021","unstructured":"Shi Y, Wu J, Wang Z et al (2021) Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002). J Hematol Oncol 14:12. https:\/\/doi.org\/10.1186\/s13045-021-01033-1","journal-title":"J Hematol Oncol"},{"key":"3467_CR38","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1200\/JCO.19.01492","volume":"37","author":"PL Zinzani","year":"2019","unstructured":"Zinzani PL, Santoro A, Gritti G et al (2019) Nivolumab combined with brentuximab vedotin for relapsed\/refractory primary mediastinal large B-Cell lymphoma: efficacy and safety from the phase II CheckMate 436 study. J Clin Oncol 37:3081\u20133089. https:\/\/doi.org\/10.1200\/JCO.19.01492","journal-title":"J Clin Oncol"},{"key":"3467_CR39","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","volume":"35","author":"R Chen","year":"2017","unstructured":"Chen R, Zinzani PL, Fanale MA et al (2017) Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma. J Clin Oncol 35:2125\u20132132. https:\/\/doi.org\/10.1200\/JCO.2016.72.1316","journal-title":"J Clin Oncol"},{"key":"3467_CR40","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","volume":"17","author":"A Younes","year":"2016","unstructured":"Younes A, Santoro A, Shipp M et al (2016) Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol 17:1283\u20131294. https:\/\/doi.org\/10.1016\/S1470-2045(16)30167-X","journal-title":"Lancet Oncol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-023-03467-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-023-03467-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-023-03467-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T03:25:47Z","timestamp":1691637947000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-023-03467-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,8]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["3467"],"URL":"https:\/\/doi.org\/10.1007\/s00262-023-03467-7","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,8]]},"assertion":[{"value":"17 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Genny Guo and Wenduo He are employees of Genor Biopharma Co., Ltd., Shanghai, China. All other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and International Council for Harmonisation guidelines for Good Clinical Practice. The study protocol, amendments, and patient informed consent were approved by the independent ethics committee at each participating hospital.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all patients before screening.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}